Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving temsirolimus together with bevacizumab works
in treating patients with stage III or stage IV malignant melanoma. Temsirolimus may stop the
growth of tumor cells by blocking some of the enzymes needed for their growth. Monoclonal
antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the
ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
carry tumor-killing substances to them. Bevacizumab may also stop the growth of malignant
melanoma by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab
may kill more tumor cells.